This section shows a general overview of information for the selected study (COSU identifier) or publication (COSP identifier). Studies may have been performed by the WTSI Cancer Genome Project, or imported from the ICGC/TCGA. You can see more information on the help pages.
- Renal: FK506/rapamycin binding protein family
- Study ID
- FK506 and rapamycin are both immunosuppressant drugs which are used to prevent rejection after drug transplantation. Through inhibition of the kinase mTOR, rapamycin can block mitogenic signalling leading to an inhibition in cell proliferation. In order for rapamycin to inhibit mTOR it must be bound to an FK506 binding protein. Rapamycin has been used in combination with other anticancer agents to tackle various types of cancer. This gene set includes FK506 binding proteins and other genes in this family.
Sequencing of any given sample through the gene sets should be considered work in progress. Lack of reported mutations in any given gene for a particular sample does not necessarily imply the sample is wildtype for the gene.
- Genes Analysed
- Mutated Samples
- Total No. of Samples